Control-IQ Technology Provides Similar Glycemic Outcomes Across Two Different Continuous Glucose Monitoring Sensors

The t:slim X2 insulin pump with Control-IQ technology (Tandem Diabetes Care) is interoperable with G6 and, more recently, G7 sensors (Dexcom). CGM-derived metrics from customers who transitioned from using Control-IQ technology with G6 and then G7 sensors were compared. Median times in various glucose concentration ranges for the final 30 days of G6 use and the initial 30 days of G7 use changed by <1% and remained within consensus target recommendations for TIR (70-180 mg/dL) >70% and TBR (<70 mg/dL) <4%. Differences in sensor use, time in closed loop, and median glucose levels were clinically insignificant. Control-IQ-based pump users experienced similar outcomes and achieved excellent glycemic control with G6 or G7 sensors.